Table 2.

Odds Ratios for T2E-Negative and T2E-Positive Prostate Cancer According to Body Mass Index,^a King County, Washington, 1993–1996 and 2002–2005

BMI Variable	Controls, % (n = 1,645)	Cases
		T2E-Negative (n = 268)			T2E -Positive (n = 295)
		%	ORb	95% CI	%	ORb	95% CI
BMI at ages 18–29 yearsc,d
<21.1	25.8	23.6	1.00		21.8	1.00
21.1–22.9	25.3	31.8	1.41	0.99, 2.02	31.0	1.40	0.99, 1.99
23.0–24.4	26.6	24.3	1.01	0.69, 1.46	29.3	1.23	0.87, 1.76
≥24.5	22.4	20.2	1.04	0.70, 1.54	18.0	0.92	0.62, 1.36
P for trend			0.70			0.59
Continuous (per 5-unit increment)			0.96	0.78, 1.19		0.83	0.68, 1.03
Recent BMI
<24.5	27.5	27.6	1.00		30.9	1.00
24.5–26.6	23.6	27.2	1.15	0.81, 1.64	27.1	1.06	0.76, 1,48
26.7–29.6	24.1	24.6	1.03	0.72, 1.48	25.1	0.98	0.70, 1.37
≥29.7	24.8	20.5	0.87	0.59, 1.27	17.0	0.66	0.45, 0.97
P for trend			0.42			0.05
Continuous (per 5-unit increment)			0.93	0.80, 1.09		0.86	0.73, 1.00
Maximum BMI
<25.9	27.0	27.2	1.00		28.1	1.00
25.9–28.2	23.2	24.6	1.05	0.73, 1.50	26.1	1.10	0.78, 1.56
28.3–31.7	25.4	28.4	1.14	0.81, 1.62	29.8	1.16	0.83, 1.62
≥31.8	24.4	19.8	0.86	0.58, 1.26	15.9	0.69	0.47, 1.02
P for trend			0.65			0.18
Continuous (per 5-unit increment)			0.95	0.82, 1.10		0.87	0.75, 1.01

Abbreviations: BMI, body mass index; CI, confidence interval; ERG, ETS-related gene; ETS, erythroblast transformation-specific; OR, odds ratio; T2E, TMPRSS2:ERG gene fusion; TMPRSS2, transmembrane protease, serine 2, gene.

^a Weight (kg)/height (m)².

^b Adjusted for age, race, and history of diabetes. One control had missing data for history of diabetes.

^c Two controls had missing data for BMI at ages 18–29 years.

^d Five controls, 1 T2E-positive case, and 1 T2E-negative case with BMIs less than 16.5 at ages 18–29 years were excluded from these analyses.